Cerus CERS Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Bio-Rad LaboratoriesBIO

——

Protagonist TherapeuticsPTGX

——

Other financials

Income statement

See full

Revenue$53.7M+24.1%

Operating income-$354.0K+94.0%

Net income-$1.6M+78.7%

EPS (diluted)-$0.01+75.0%

Balance sheet

See full

Cash & equivalents$27.9M+43.0%

Total debt$45.0M-43.3%

Total equity$67.6M+21.7%

Total assets$222.9M+7.8%

Cash flow

See full

Operating cash flow-$3.0M-261%

CapEx$233.0K+108%

Free cash flow-$3.3M-243%

Valuation

See full

Market cap$573.06M+124%

Enterprise value$590.17M+86.7%

P/S2.9×-1.0×

Profitability

See full

Gross margin64%—

Operating margin-6.2%-2.1pp

Net margin-9.8%-2.8pp

FCF margin3.5%+1.9pp

Returns & leverage

See full

Return on equity-15.5%-5.6pp

Debt / equity0.7×-0.8×

Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cerus's proceeds from exercises of stock options and other stock issuances?: Cerus (CERS) reported proceeds from exercises of stock options and other stock issuances of $263K in Q1 2026.
How has Cerus's proceeds from exercises of stock options and other stock issuances changed year-over-year?: Cerus's proceeds from exercises of stock options and other stock issuances decreased by 19.3% year-over-year, from $326K to $263K.